fourth-generation reversible EGFR T790M mutant-selective inhibitors (Genosco/Yuhan)

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug Namefourth-generation reversible EGFR T790M mutant-selective inhibitors (Genosco/Yuhan)
Drug Alias Namefourth-generation reversible EGFR T790M mutant-selective inhibitors (Genosco/Yuhan)SKI-O-751
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-6 inhibitorsTumor necrosis factor α inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsInterleukin-6Epidermal growth factor receptor erbB1Tumor necrosis factor α
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenosco
China Registration ClassN/A

Develop Information

Active CompaniesGenoscoYuhan Corp
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A